CU20170044A7 - Método mejorado para producir una composición de partículas enterovirales a través de la inactivación del enterovirus y la adsorción en coadyuvantes - Google Patents

Método mejorado para producir una composición de partículas enterovirales a través de la inactivación del enterovirus y la adsorción en coadyuvantes

Info

Publication number
CU20170044A7
CU20170044A7 CUP2017000044A CU20170044A CU20170044A7 CU 20170044 A7 CU20170044 A7 CU 20170044A7 CU P2017000044 A CUP2017000044 A CU P2017000044A CU 20170044 A CU20170044 A CU 20170044A CU 20170044 A7 CU20170044 A7 CU 20170044A7
Authority
CU
Cuba
Prior art keywords
improved method
coadyuvants
adsortion
produce
composition
Prior art date
Application number
CUP2017000044A
Other languages
English (en)
Other versions
CU24510B1 (es
Inventor
Rajeev Mhalasakant Dhere
Sambhaji Shankar Pisal
Rajendra Narayan Sabale
Jagdish Kamalaji Zade
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of CU20170044A7 publication Critical patent/CU20170044A7/es
Publication of CU24510B1 publication Critical patent/CU24510B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32663—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32671—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

<p>Método mejorado para inactivar enterovirus con formaldehído en presencia de tampón de trometamina para obtener una recuperación máxima del antígeno D. Mediante Ia adsorción posterior de sIPV en hidróxido de aluminio, las composiciones de sIPV se obtienen a dosis significativamente reducidas.</p>
CU2017000044A 2014-10-07 2015-10-06 Método para la composición de una vacuna contra la poliomielitis, con poliovirus inactivados y adsorción en coadyuvantes CU24510B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3180MU2014 2014-10-07
PCT/IN2015/000376 WO2016063291A1 (en) 2014-10-07 2015-10-06 Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Publications (2)

Publication Number Publication Date
CU20170044A7 true CU20170044A7 (es) 2018-09-05
CU24510B1 CU24510B1 (es) 2021-05-12

Family

ID=55300742

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000044A CU24510B1 (es) 2014-10-07 2015-10-06 Método para la composición de una vacuna contra la poliomielitis, con poliovirus inactivados y adsorción en coadyuvantes

Country Status (24)

Country Link
US (1) US10485862B2 (es)
EP (2) EP3663396A1 (es)
JP (2) JP6755243B2 (es)
KR (2) KR102510744B1 (es)
CN (2) CN113368227A (es)
AU (2) AU2015334495B2 (es)
BR (1) BR112017007089A2 (es)
CA (1) CA2963897C (es)
CU (1) CU24510B1 (es)
CY (1) CY1123078T1 (es)
DK (1) DK3204494T3 (es)
EA (1) EA201700187A1 (es)
ES (1) ES2803578T3 (es)
HU (1) HUE049104T2 (es)
LT (1) LT3204494T (es)
MX (1) MX2017004534A (es)
PE (1) PE20171132A1 (es)
PH (1) PH12017500627A1 (es)
PL (1) PL3204494T3 (es)
PT (1) PT3204494T (es)
SG (2) SG10202010814RA (es)
SI (1) SI3204494T1 (es)
UA (1) UA125788C2 (es)
WO (1) WO2016063291A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3204494T (lt) * 2014-10-07 2020-07-10 Serum Institute Of India Private Limited Polioviruso inaktyvavimo, adjuvanto adsorpcijos pagerinti būdai
CA3022602A1 (en) 2016-05-10 2017-11-16 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
PE20200004A1 (es) * 2016-08-26 2020-01-06 Serum Institute Of India Pvt Ltd Composicion de vacuna multivalente novedosa
TWI711700B (zh) * 2017-07-10 2020-12-01 印度商印度血清研究公司 使腸病毒去活化之改良方法、佐劑吸附及所獲得之劑量減少的疫苗組成物
BR112020008652A2 (pt) 2017-11-03 2020-11-10 Takeda Vaccines, Inc. vacinas e composições imunogênicas contra zika e métodos de uso das mesmas
AU2018375173B2 (en) 2017-11-30 2022-08-25 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
EP3749757A4 (en) 2018-02-07 2021-11-24 Bharat Biotech International Limited PROCEDURES FOR ENTEROVIRUS CLEANING AND INACTIVATION AND VACCINE COMPOSITIONS RESULTED FROM THEM
CN109550046B (zh) * 2018-12-21 2020-08-25 北京民海生物科技有限公司 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283565B6 (sk) * 1996-07-02 2003-09-11 Connaught Laboratories Limited Multivalentná imunogénna kompozícia a jej použitie
EP1793852A1 (en) * 2004-08-27 2007-06-13 Panacea Biotec Ltd. Inactivated poliomyelitis vaccine derived from sabin strain of polio virus
CN1647822A (zh) * 2005-02-06 2005-08-03 北京生物制品研究所 脊髓灰质炎灭活疫苗及其制备方法
ES2387582T3 (es) * 2006-09-07 2012-09-26 Glaxosmithkline Biologicals S.A. Vacuna de combinación con cantidades reducidas del antígeno del virus de la polio
CN100540662C (zh) * 2006-12-06 2009-09-16 云南沃森生物技术有限公司 一种混合床凝胶过滤层析技术用于病毒性疫苗纯化的方法
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
WO2011074006A2 (en) * 2009-12-16 2011-06-23 Serum Institute Of India Ltd. Vaccine composition
RU2013144207A (ru) * 2011-03-02 2015-04-10 Новартис Аг Комбинированные вакцины с пониженными дозами антигена и/или адъюванта
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
LT3204494T (lt) * 2014-10-07 2020-07-10 Serum Institute Of India Private Limited Polioviruso inaktyvavimo, adjuvanto adsorpcijos pagerinti būdai

Also Published As

Publication number Publication date
NZ731341A (en) 2023-11-24
SG10202010814RA (en) 2020-12-30
US20170348411A1 (en) 2017-12-07
EA201700187A1 (ru) 2017-12-29
LT3204494T (lt) 2020-07-10
KR102219638B1 (ko) 2021-02-23
AU2021269395A1 (en) 2021-12-16
EP3663396A1 (en) 2020-06-10
MX2017004534A (es) 2017-10-11
CY1123078T1 (el) 2021-10-29
UA125788C2 (uk) 2022-06-08
DK3204494T3 (da) 2020-07-06
SI3204494T1 (sl) 2020-08-31
SG11201702838SA (en) 2017-05-30
JP6755243B2 (ja) 2020-09-16
JP7063957B2 (ja) 2022-05-09
WO2016063291A1 (en) 2016-04-28
PT3204494T (pt) 2020-07-10
US10485862B2 (en) 2019-11-26
BR112017007089A2 (pt) 2017-12-26
EP3204494B1 (en) 2020-04-01
JP2020203906A (ja) 2020-12-24
HUE049104T2 (hu) 2020-08-28
KR20210021148A (ko) 2021-02-24
PH12017500627A1 (en) 2017-09-25
CA2963897C (en) 2023-08-22
CN106999569A (zh) 2017-08-01
AU2015334495A1 (en) 2017-05-25
KR102510744B1 (ko) 2023-03-15
CN113368227A (zh) 2021-09-10
PE20171132A1 (es) 2017-08-09
KR20170063947A (ko) 2017-06-08
EP3204494A1 (en) 2017-08-16
ES2803578T3 (es) 2021-01-28
CN106999569B (zh) 2021-06-29
AU2015334495B2 (en) 2021-08-19
JP2017533899A (ja) 2017-11-16
PL3204494T3 (pl) 2020-09-21
CA2963897A1 (en) 2016-04-28
CU24510B1 (es) 2021-05-12

Similar Documents

Publication Publication Date Title
CU20170044A7 (es) Método mejorado para producir una composición de partículas enterovirales a través de la inactivación del enterovirus y la adsorción en coadyuvantes
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
TR201907106T4 (tr) Bir transplant alıcısında immünosüpresif terapileri izleme yöntemleri.
EA202090547A2 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
MX2020004542A (es) Metodo para inactivar el virus del zika y para determinar la inactivacion total.
MX2021010060A (es) Produccion de virus en huevos aviares.
CR20140189S (es) Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue
IN2014MU00455A (es)
CL2016002442A1 (es) Rnasa para su uso en el tratamiento o la prevención de infecciones virales.
PH12015502115A1 (en) Compositions and methods for live, attenuated alphavirus formulations
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
CL2018000253A1 (es) Respuesta inmunitaria potenciada de las especies porcinas
UY34840A (es) Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos
PH12016501854B1 (en) A non-naturally occuring porcine reproductive and respiratory syndrome virus (prrsv) and methods of using
AR106090A1 (es) Métodos y formulaciones para reducir las emisiones de bovino
AR109244A1 (es) Métodos mejorados para la inactivación de enterovirus y la adsorción sobre coadyuvantes, y composiciones de vacunas con dosis reducidas obtenidas con ellos
CL2015002913A1 (es) Disposición y método en una caldera de recuperación de soda
MX2018011226A (es) Tc24-c4, antígeno de vacuna de la enfermedad de chagas con estabilidad mejorada y agregación disminuida.
AR095118A1 (es) Un procedimiento de inactivación viral en composición que comprende factor vii